Driver oncogenes in many types of cancer encode growth factor receptors belonging to the receptor tyrosine kinase (RTK) superfamily, and most molecularly targeted therapies successfully incorporated into clinical practice to date act by targeting RTKs [1,2]. Here, NTRK1 is linked to cancer.